Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A06186 | Pages: 221 | Charts: 41 | Tables: 112 |
The global heparin market size was valued at $6,535 million in 2020, and is projected to reach $11,015 million by 2028, registering a CAGR of 6.6% from 2021 to 2028. Heparin, also known as unfractionated heparin (UFH), is a glycosaminoglycan that occurs naturally. It is used as an anticoagulant in medicine (blood thinner). It is particularly useful for the treatment of heart attacks and unstable angina. It is injected into a vein or injected under the skin. It is used to treat a variety of health problems, such as acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during cardiac surgery. Its use also extends to the administration of major orthopedic procedures such as hip and knee replacements.
Get more information on this report : Request Sample Pages
The increase in prevalence of venous thrombosis and cardiovascular diseases is the key factor that drives the growth of the global heparin market. In addition, application of heparin in various surgeries, such as orthopedic and heart surgeries, and rise in number of patients undergoing such surgeries further boost the growth of the heparin market. Moreover, the availability of synthetic and semi-synthetic heparin mimetics that help treat cancer, coagulation, and inflammatory diseases is expected to provide lucrative opportunities for heparin adoption. In addition, increased government support for healthcare infrastructure improvements and comprehensive R&D activities to grow heparin with enhanced therapeutic potential and minimum side effects further drive the growth of the heparin market. However, many adverse side-effects associated with heparin and presence of other anticoagulant in the market may hamper the growth of the heparin market.
The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including heparin. During the COVID-19 pandemic, a large number of patients are suffering from coronavirus, which is linked to respiratory diseases. As a result, the demand for heparin has increased as it helps to control respiratory inflation and thin the blood of those at risk of a blood clot. Low molecular weight heparins are anticoagulant medications that are well tolerated and have few side effects.
Regardless of risk ratings, all patients admitted to the hospital with (suspected) COVID-19 are treated with prophylactic-dose low-molecular-weight heparin. A baseline chest CT is performed on patients who have COVID-19 symptoms and are anticipated to be admitted to the hospital. The study of the binding of LMWH with SARS-CoV-2 Spike protein could lead to the development of an effective therapeutic approach to reduce pulmonary embolism and thrombosis complications in SARS-CoV-2 patients. As a result, LMWH used in the treatment of COVID-19 patients and clinical study & development continue in these pandemic times to improve LMWH's efficacy.
The global heparin market is segmented into product, application, distribution channel, and region. On the basis of product, the market is categorized into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By application, it is classified into venous thromboembolism, atrial fibrillation, coronary artery disease, and others. By distribution channel, it is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Based on product, the low molecular weight heparin segment currently dominates the global market and is expected to continue during the forecast period. Longer and more predictable operation than UFH and easy self-administration at home by subcutaneous injection, which decreases or eliminates hospital stays, and no requirement of daily blood monitoring are all important factors that boost the heparin market growth.
[PRODUCTGRAPH]
Get more information on this report : Request Sample Pages
Based on distribution channel, the hospital pharmacies segment accounted for majority of the market revenue in 2020 and is expected to maintain its dominance during the forecast period as patients' trust in hospitals is based on high-quality services and easy access to medications as well as greater reliance on healthcare professionals for heparin prescriptions.
[DISTRIBUTIONCHANNELGRAPH]
Get more information on this report : Request Sample Pages
Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period, owing to constantly expanding healthcare infrastructure, presence of untapped resources, economic development, and increasing initiatives by private & public organizations, which are projected to drive the growth of the heparin market in emerging countries in Asia-Pacific. In addition, larger patient pool for cardiovascular diseases and an increase in the aging population are some factors, which drive the growth of the market. Moreover, increase in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the heparin market in the region.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
The key market players profiled in the report include Baxter International Inc., B. Braun Holding GmbH & Co. KG, Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co KGaA, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Leo Pharma A/S, Pfizer Inc., Sanofi S.A, Teva Pharmaceuticals, and Viatris Inc.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidence of venous thromboembolism and cardiovascular disorders
3.5.1.2.Rise in geriatric population
3.5.1.3.Increase in usage of heparin in surgical procedures
3.5.2.Restraints
3.5.2.1.Side effects associated with heparin
3.5.2.2.Presence of alternative anticoagulants
3.5.3.Opportunities
3.5.3.1.Availability of synthetic and semi-synthetic heparin mimetics
3.5.3.2.R&D activities to develop heparin with improved therapeutic
3.5.4.Impact analysis
3.6Covid-19 Impact analysis on heparin market
CHAPTER 4:HEPARIN MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Unfractionated Heparin
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Low Molecular Weight Heparin (LMWH)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Ultra-low Molecular Weight Heparin (ULMWH)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
CHAPTER 5:HEPARIN MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Venous Thromboembolism
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Coronary Artery Disease
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Atrial Fibrillation
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Others
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
CHAPTER 6:HEPARIN MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug stores and retail pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online pharmacies
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:HEPARIN MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. heparin market, by product
7.2.2.1.2.U.S. heparin market, by application
7.2.2.1.3.U.S. heparin market, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Canada heparin market, by product
7.2.2.2.2.Canada heparin market, by application
7.2.2.2.3.Canada heparin market, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico heparin market, by product
7.2.2.3.2.Mexico heparin market, by application
7.2.2.3.3.Mexico heparin market, by distribution channel
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany heparin market, by product
7.3.2.1.2.Germany heparin market, by application
7.3.2.1.3.Germany heparin market, by distribution channel
7.3.2.2.France
7.3.2.2.1.France heparin market, by product
7.3.2.2.2.France heparin market, by application
7.3.2.2.3.France heparin market, by distribution channel
7.3.2.3.UK
7.3.2.3.1.UK heparin market, by product
7.3.2.3.2.UK heparin market, by application
7.3.2.3.3.UK heparin market, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Italy heparin market, by product
7.3.2.4.2.Italy heparin market, by application
7.3.2.4.3.Italy heparin market, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Spain heparin market, by product
7.3.2.5.2.Spain heparin market, by application
7.3.2.5.3.Spain heparin market, by distribution channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe heparin market, by product
7.3.2.6.2.Rest of Europe heparin market, by application
7.3.2.6.3.Rest of Europe heparin market, by distribution channel
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan heparin market, by product
7.4.2.1.2.Japan heparin market, by application
7.4.2.1.3.Japan heparin market, by distribution channel
7.4.2.2.China
7.4.2.2.1.China heparin market, by product
7.4.2.2.2.China heparin market, by application
7.4.2.2.3.China heparin market, by distribution channel
7.4.2.3.India
7.4.2.3.1.India heparin market, by product
7.4.2.3.2.India heparin market, by application
7.4.2.3.3.India heparin market, by distribution channel
7.4.2.4.Australia
7.4.2.4.1.Australia heparin market, by product
7.4.2.4.2.Australia heparin market, by application
7.4.2.4.3.Australia heparin market, by distribution channel
7.4.2.5.Rest of Asia-Pacific
7.4.2.5.1.Rest of Asia-Pacific heparin market, by product
7.4.2.5.2.Rest of Asia-Pacific heparin market, by application
7.4.2.5.3.Rest of Asia-Pacific heparin market, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil heparin market, by product
7.5.2.1.2.Brazil heparin market, by application
7.5.2.1.3.Brazil heparin market, by distribution channel
7.5.2.2.South Africa
7.5.2.2.1.South Africa heparin market, by product
7.5.2.2.2.South Africa heparin market, by application
7.5.2.2.3.South Africa heparin market, by distribution channel
7.5.2.3.Saudi Arabia
7.5.2.3.1.Saudi Arabia heparin market, by product
7.5.2.3.2.Saudi Arabia heparin market, by application
7.5.2.3.3.Saudi Arabia heparin market, by distribution channel
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA heparin market, by product
7.5.2.4.2.Rest of LAMEA heparin market, by application
7.5.2.4.3.Rest of LAMEA heparin market, by distribution channel
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.Baxter International Inc.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segment
8.1.4.Product portfolio
8.1.5.Business performance
8.2.B. Braun Holding GmbH & Co. KG
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance
8.3.Dr. Reddy’s Laboratories Ltd.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance
8.4.Fresenius SE & Co KGaA
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segment
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segment
8.5.4.Product portfolio
8.6.Leo Pharma A/S
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Pfizer Inc.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.Sanofi S.A.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Teva Pharmaceuticals
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance
8.10.Viatris Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Operating business segments
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.HEPARIN MARKET, BY PRODUCT, 2020-2028 ($MILLION)
TABLE 02.UNFRACTIONATED HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 04.ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.HEPARIN MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 06.VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 07.CORONARY ARTERY DISEASE HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 08.ATRIAL FIBRILLATION HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 09.OTHERS HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 10.HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 11.HOSPITAL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 12.DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 13.ONLINE PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 14.HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 15.NORTH AMERICA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 16.U.S. HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 17.U.S. HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 18.U.S. HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 19.CANADA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 20.CANADA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 21.CANADA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 22.MEXICO HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 23.MEXICO HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 24.MEXICO HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 25.NORTH AMERICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 26.NORTH AMERICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 27.NORTH AMERICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 28.EUROPE HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 29.GERMANY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 30.GERMANY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 31.GERMANY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 32.FRANCE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 33.FRANCE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 34.FRANCE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 35.UK HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 36.UK HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 37.UK HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 38.ITALY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 39.ITALY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 40.ITALY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 41.SPAIN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 42.SPAIN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 43.SPAIN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 44.REST OF EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 45.REST OF EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 46.REST OF EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 47.EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 48.EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 49.EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 50.ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 51.JAPAN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 52.JAPAN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 53.JAPAN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 54.CHINA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 55.CHINA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 56.CHINA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 57.INDIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 58.INDIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 59.INDIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 60.AUSTRALIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 61.AUSTRALIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 62.AUSTRALIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 63.REST OF ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 64.REST OF ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 65.REST OF ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 66.ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 67.ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 68.ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 69.LAMEA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 70.BRAZIL HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 71.BRAZIL HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 72.BRAZIL HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 73.SOUTH AFRICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 74.SOUTH AFRICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 75.SOUTH AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 76.SAUDI ARABIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 77.SAUDI ARABIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 78.SAUDI ARABIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 79.REST OF LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 80.REST OF LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 81.REST OF LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 82.LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 83.LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 84.LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 85.BAXTER: COMPANY SNAPSHOT
TABLE 86.BAXTER: OPERATING SEGMENTS
TABLE 87.BAXTER: PRODUCT PORTFOLIO
TABLE 88.B. BRAUN: COMPANY SNAPSHOT
TABLE 89.B. BRAUN: OPERATING SEGMENTS
TABLE 90.B.BRAUN: PRODUCT PORTFOLIO
TABLE 91.DR. REDDY’S LAB: COMPANY SNAPSHOT
TABLE 92.DR. REDDY’S LAB: OPERATING SEGMENTS
TABLE 93.DR. REDDY’S LAB: PRODUCT PORTFOLIO
TABLE 94.FRESENIUS: COMPANY SNAPSHOT
TABLE 95.FRESENIUS: OPERATING SEGMENTS
TABLE 96.FRESENIUS: PRODUCT PORTFOLIO
TABLE 97.HEBEI: COMPANY SNAPSHOT
TABLE 98.FRESENIUS: OPERATING SEGMENTS
TABLE 99.HEBEI: PRODUCT PORTFOLIO
TABLE 100.LEO: COMPANY SNAPSHOT
TABLE 101.LEO: OPERATING SEGMENTS
TABLE 102.IBM: PRODUCT PORTFOLIO
TABLE 103.PFIZER: COMPANY SNAPSHOT
TABLE 104.PFIZER: OPERATING SEGMENTS
TABLE 105.PFIZER: PRODUCT PORTFOLIO
TABLE 106.SANOFI: COMPANY SNAPSHOT
TABLE 107.SANOFI: OPERATING SEGMENTS
TABLE 108.SANOFI: PRODUCT PORTFOLIO
TABLE 109.ASPEN: COMPANY SNAPSHOT
TABLE 110.TEVA: PRODUCT PORTFOLIO
TABLE 111.VIATRIS: COMPANY SNAPSHOT
TABLE 112.VIATRIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL HEPARIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.HIGH THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF UNFRACTIONATED HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF ATRIAL FIBRILLATION HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OTHERS HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 18.BAXTER: REVENUE, 2018–2020 ($MILLION)
FIGURE 19.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.BAXTER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 21.B BRAUN: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.B BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.B BRAUN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 24.DR. REDDY’S LAB: REVENUE, 2018–2020 ($MILLION)
FIGURE 25.DR. REDDY’S LAB: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.DR. REDDY’S LAB: REVENUE SHARE BY REGION 2020 (%)
FIGURE 27.FRESENIUS: REVENUE, 2018–2020 ($MILLION)
FIGURE 28.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.FRESENIUS: REVENUE SHARE BY REGION 2020 (%)
FIGURE 30.LEO: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.LEO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.LEO: REVENUE SHARE BY REGION 2020 (%)
FIGURE 33.PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 34.PFIZER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 35.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 36.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 39.TEVA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.VIATRIS: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)